A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Status:
RECRUITING
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.